文献速递膀胱癌与上尿路尿路上皮癌

PURE-01 试验:新辅助帕博利珠单抗后根治性膀胱切除与盆腔淋巴结清扫的手术安全性前瞻评估

Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial.
PubMed 文献 · Eur Urol · 2020-01-03

PURE-01 试验前瞻性评估 68 例接受三程新辅助帕博利珠单抗的 MIBC 患者,随后行开放或机器人辅助根治性膀胱切除与盆腔淋巴结清扫;90 天内任何级别并发症 77%、≥2 级 69%、再入院 32%、高 grade 34%,无围手术期死亡。

要点

  • 新辅助帕博利珠单抗后 RC+PLND 未增加围手术期死亡,90 天死亡为 0。
  • 90 天任何级别并发症 77%,≥2 级 69%,Clavien-Dindo ≥3a 34%。
  • 最常见并发症为发热 52% 和肠梗阻 31%。

核心结论

  • PURE-01 试验提供首个前瞻性证据,支持 N0M0 MIBC 患者接受新辅助帕博利珠单抗后行 RC 和 PLND 的手术安全性。
  • 90 天内无围手术期死亡,但任何级别和高 grade 并发症发生率较高。

研究设计与样本

  • 前瞻性队列研究,纳入 2017 年 2 月至 2019 年 6 月单中心 68 例连续接受三程 200 mg 帕博利珠单抗每 3 周静脉给药后行开放或机器人辅助 RC 和 PLND 的 MIBC 患者。
  • 术后并发症按 Clavien-Dindo 系统分级,围手术期数据在术后 90 天按 EAU 指南推荐前瞻性系统收集。

主要发现

  • 52 例(77%)行机器人辅助 RC,16 例(23%)行开放 RC;31 例(46%)接受原位新膀胱。
  • 中位失血量 150 ml,中位住院时间 12 天。
  • 90 天内任何级别并发症 52 例(77%),≥2 级并发症 47 例(69%),再入院 22 例(32%)。
  • Clavien-Dindo ≥3a 高 grade 并发症 23 例(34%)。
  • 最常见并发症为发热 35 例(52%)和肠梗阻 21 例(31%);90 天围手术期死亡 0 例。

临床怎么用

  • 对于计划接受新辅助帕博利珠单抗的 N0M0 MIBC 患者,可参考本数据评估 RC 和 PLND 的围手术期风险。
  • 术后 90 天内应重点关注发热和肠梗阻,并做好高 grade 并发症和再入院的监测与预案。

局限性

  • 单中心、高容量三级转诊中心的前瞻性队列,样本量 68 例。
  • 非随机对照设计,未与未接受新辅助免疫治疗的历史或同期队列直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

No data are available on the surgical safety of radical cystectomy (RC) and pelvic lymph node dissection (PLND) after the administration of checkpoint inhibitors. We aimed at reporting the first prospective rigorous assessment of perioperative outcomes after RC and extended PLND following neoadjuvant pembrolizumab in a contemporary cohort of patients with muscle-invasive bladder cancer (MIBC) enrolled in the PURE-01 trial. From February 2017 to June 2019, a total of 68 consecutive patients who received three courses of 200 mg pembrolizumab intravenously every 3 wk and were subsequently treated with either open or robot-assisted RC and PLND at a single high-volume tertiary referral center were identified. All men had prospectively collected data about intra- and postoperative outcomes. Postoperative complications were graded according to the Clavien-Dindo system. Perioperative data were prospectively and systematically collected during patient interviews at 90 d after surgery according to the European Association of Urology (EAU) Guidelines Panel recommendations on reporting and grading complications. Overall, 52 (77%) versus 16 (23%) patients underwent robot-assisted versus open RC, and 31 patients (46%) received an orthotopic neobladder. Median blood loss and length of stay were 150 ml and 12 d, respectively. Overall, 52 (77%), 47 (69%), and 22 (32%) patients experienced any-grade complications, grade ≥2 complications, and readmission at 90 d, respectively. High-grade complications (defined as Clavien-Dindo ≥3a) were observed in 23 patients (34%). The most frequent complications were fever (n = 35, 52%) and ileus (n = 21, 31%). None of the patients experienced perioperative mortality at 90 d. Our data represent the first prospective evidence supporting the surgical safety of RC and PLND in patients with N0M0 MIBC who received neoadjuvant immunotherapy with pembrolizumab. PATIENT SUMMARY: The current study represents the first prospective evidence supporting the surgical safety of radical cystectomy and pelvic lymph node dissection in patients with nonmetastatic bladder cancer who received neoadjuvant immunotherapy with pembrolizumab.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Briganti A, Gandaglia G, Scuderi S, et al. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. Eur Urol. 2020. PMID: 31911010. doi:10.1016/j.eururo.2019.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。